High serum levels of IGF-I and IGFBP3 may increase comorbidity risk for asthmatic patients


Creative Commons License

ACAT M., ERBAY Ü., ŞAHİN S., ARIK Ö. , AYADA C.

BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, cilt.118, ss.691-694, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 118 Konu: 11
  • Basım Tarihi: 2017
  • Doi Numarası: 10.4149/bll_2017_130
  • Dergi Adı: BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY
  • Sayfa Sayıları: ss.691-694

Özet

OBJECTIVE: Asthma is known as a chronic inflammatory lung disease which has also systemic features. Insulin-like growth factor I (IGF-I) plays a role for asthma pathogenesis. Controversially, IGF-binding protein 3 (IGFBP3) blocks asthma development. That is why IGF-I and IGFBP3 are targeted for future therapeutic treatments of asthma. We aimed to investigate serum level of IGF-I and IGFBP3 in patients with asthma. This study was performed in 27 asthma and 23 healthy individuals. Serum levels of IGF-I and IGFBP3 were measured by human ELISA assay kits. Serum levels of IGF-I and IGFBP3 were significanlty higher in the asthma group than the control group. Significant negative correlation was found between IGF-I and asthma control test (ACT) puan, O-2 saturation, Forced Expiratory Volume in 1 second/ Forced Vital Capacity (FEV1/FVC), Forced Expiratory Flow 25 second/75 second (FEF2575) (%). Significant positive correlation was found between IGFBP3 and IGF-I, systolic blood pressure. Significant negative correlation was found between IGF-I and FEV1 (ml).